Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (71-80 of 303) with videos related to

Pageof 31
Sort By:
Expert Opinion on Pharmacotherapy|August 2, 2020
Evaluating entrectinib as a treatment option for non-small cell lung cancerJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2020
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinomaJiyun Lee, Yoon La Choi, Hyun Ae Jung, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2025
Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamabGeun-Ho Park, Sehhoon Park, Hyemin Kim, et al.
Investigational New Drugs|January 1, 2022
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancerBo Mi Ku, Jae Yeong Heo, Jinchul Kim, et al.
Oncology|February 23, 2022
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR InhibitorBo Mi Ku, Yeon Jeong Kim, Donghyun Park, et al.
Oncotarget|September 30, 2016
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgeryWon Kyung Cho, Dongryul Oh, Yong Chan Ahn, et al.
Oncotarget|October 6, 2017
Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancerBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Investigational New Drugs|April 6, 2016
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cellsBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Frontiers in Oncology|June 4, 2026
Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLCJinyong Kim, Geun-Ho Park, Sehhoon Park, et al.
Cancer Research and Treatment|July 1, 2020
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M MutationSehhoon Park, Bo Mi Ku, Hyun Ae Jung, et al.
Pageof 31

Showing results (71-80 of 303) with videos related to

Sort By:
Pageof 31
Expert Opinion on Pharmacotherapy|August 2, 2020
Evaluating entrectinib as a treatment option for non-small cell lung cancerJiyun Lee, Sehhoon Park, Hyun Ae Jung, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2020
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinomaJiyun Lee, Yoon La Choi, Hyun Ae Jung, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2025
Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamabGeun-Ho Park, Sehhoon Park, Hyemin Kim, et al.
Investigational New Drugs|January 1, 2022
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancerBo Mi Ku, Jae Yeong Heo, Jinchul Kim, et al.
Oncology|February 23, 2022
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR InhibitorBo Mi Ku, Yeon Jeong Kim, Donghyun Park, et al.
Oncotarget|September 30, 2016
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgeryWon Kyung Cho, Dongryul Oh, Yong Chan Ahn, et al.
Oncotarget|October 6, 2017
Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancerBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Investigational New Drugs|April 6, 2016
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cellsBo Mi Ku, Yeon-Hee Bae, Jiae Koh, et al.
Frontiers in Oncology|June 4, 2026
Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLCJinyong Kim, Geun-Ho Park, Sehhoon Park, et al.
Cancer Research and Treatment|July 1, 2020
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M MutationSehhoon Park, Bo Mi Ku, Hyun Ae Jung, et al.
Pageof 31